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Prevalence of Treated Epilepsy in Korea Based on National 
Health Insurance Data
The Korean national health security system covers the entire population and all medical 
facilities. We aimed to estimate epilepsy prevalence, anticonvulsant utilization pattern and 
the cost. We identified prevalent epilepsy patients by the prescription of anticonvulsants 
under the diagnostic codes suggesting seizure or epilepsy from 2007 Korean National 
Health Insurance databases. The information of demography, residential area, the kind of 
medical security service reflecting economic status, anticonvulsants, and the costs was 
extracted. The overall prevalence of treated epilepsy patients was 2.41/1,000, and higher 
for men than women. The age-specific prevalence was the lowest in those in their thirties 
and forties. Epilepsy was more prevalent among lower-income individuals receiving 
medical aid. The regional prevalence was the highest in Jeju Island and lowest in Ulsan city. 
New anticonvulsants were more frequently used than old anticonvulsants in the younger 
age group. The total annual cost of epilepsy or seizure reached 0.46% of total medical 
expenditure and 0.27% of total expenditure on health. This is the first nationwide 
epidemiological report issued on epilepsy in Korea. Epilepsy prevalence in Korea is 
comparable to those in developed countries. Economic status and geography affect the 
prevalence of epilepsy. 
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INTRODUCTION
The prevalence of epilepsy has been reported to be 2.2-41.0/1,000 
in diverse populations and to be affected by ethnicity and socio-
economic status (1). In Korea, no epidemiological data for epi-
lepsy exist despite the presence of all state-of-the-art medical 
technologies required for the diagnosis and treatment of epi-
lepsy, such as high resolution neuroimaging studies, the newest 
anticonvulsants, and various neurostimulation methods, are 
available. 
  Korea has a unique health security system, which is run by 
the government and based on a health insurance scheme that 
encompasses the entire population and all medical facilities. 
The scheme covers medical expenses approved for the control 
of most diseases, which include epilepsy, and Korean Health 
Insurance database contains details of all medications, medical 
services, and diagnoses for claims made.
  Accordingly, the Korean National Health Insurance (NHI) da-
tabase provides a useful and reliable source of epidemiologic 
data, and allows nationwide studies in unselected populations. 
A number of recent epidemiological reports based on NHI data 
have been issued on stroke (2), multiple sclerosis (3), psychiat-
ric illness (4), hip fracture (5), asthma (6), and appendicitis (7) 
in Korea. National registration or health insurance databases 
have also been used for the epidemiologic study of epilepsy in 
the UK (8), Finland (9), Denmark (10), and in the US (11).
  The aim of the study was to esimate the prevalence of treated 
epilepsy in Korea, and document anticonvulsant prescribing 
patterns and medical costs. This study represents the first phase 
of an epidemiology project initiated by the Korean Epilepsy So-
ciety.
MATERIALS AND METHODS
Study population and data sources
Korea occupies the southern Korean peninsula in East Asia, and Lee S-Y, et al.  •  Prevalence of Epilepsy in Korea
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its population is almost completely composed of ethnic Koreans. 
In the present study, we used the 2007 databases of the Korean 
National Health Insurance Cooperation (NHIC) and the Health 
Insurance Review and Assessment Service (HIRA); both are gov-
ernmental agencies that supervise all medical services in Korea. 
  The Korean health security system is based on an obligatory 
national health insurance scheme. Medical aid is provided through 
a social welfare fund for 3.73% (12) of the population unable to 
pay the insurance premium. All other citizens are obliged to join 
the national health insurance scheme. In 2007, the number of 
beneficiaries was 49,672,388 which closely approximates the total 
population based on 2005 census figures (47,041,434) and the 
population estimated for 2007 using the cohort component meth-
od (48,456,369) (13). A total of 1,943 hospitals, 26,141 private 
clinics, 3,445 public health centers, and 20,730 pharmacies were 
registered (12). Medical facilities claim costs from the NHIC, then 
HIRA assesses the claims based on diagnostic codes and medi-
cal records. All medical costs associated with epilepsy treatment, 
including laboratory examinations, medications, surgery, and 
hospitalization, are covered by the health security system and 
all related records are stored in the NHIC and HIRA databases.
Criteria for patient selection
Patients were considered to have epilepsy when both of the fol-
lowing criteria were fulfilled; 1) a diagnostic code for epilepsy or 
seizure, and 2) the prescription of anticonvulsants during 2007.
  The diagnostic codes of the 10th version of the International 
Classification of Diseases and Related Health Problems (ICD-10) 
for epilepsy or seizure, namely, G40* (epilepsy), G41* (status 
epilepticus), F803 (Landau-Kleffner syndrome), and R56 (con-
vulsion), were included in present study. 
  Anticonvulsants included carbamazepine, ethosuximide, ga-
bapentin, lamotrigine, levetiracetam, oxcarbazepine, phenobar-
bital, phenytoin, pregabalin, topiramate, vigabatrin, valproate, 
and zonisamide. Clonazepam was excluded because it is rarely 
used as monotherapy for epilepsy and is more frequently used 
for nonepileptic purposes. Other anticonvulsants including clo-
bazam, primidone, felbamate, and tiagabine were not available 
in Korea in 2007. Anticonvulsants were divided into two groups; 
old-generation anticonvulsants, such as, carbamazepine, etho-
suximide, phenobarbital, phenytoin, and valproate, and new-
generation anticonvulsants, such as, gabapentin, lamotrigine, 
levetiracetam, oxcarbazepine, pregabalin, topiramate, vigaba-
trin, and zonisamide. 
Estimation of prevalence and medical costs
The number of total health security system beneficiaries 
(49,672,388 persons) was used as the denominator for estimat-
ing prevalence. We estimated the one-year prevalence accord-
ing to each age group in a 10-yr interval, by gender, economic 
status, and residential area. Economic status was classified ac-
cording to the type of health security system received. Medical 
aid covered lower-income patients, and health insurance cov-
ered the remaining patients.
  Korea comprises nine provinces and seven metropolitan cit-
ies. Provinces are composed of small cities and rural areas. Met-
ropolitan cities are homogeneous urban areas that have a pop-
ulation of more than one million. Prevalence for each region was 
based on the diagnostic codes, irrespective of anticonvulsant 
prescription, because merging data for the residential areas and 
for the anticonvulsants was not permitted by privacy policy. Re-
gional prevalence was age adjusted for the 2007 overall Korean 
population.
  We assessed the annual medical costs incurred under the di-
agnosis of epilepsy or seizure for 2007 from data from health in-
surance reimbursements to hospitals, clinics, or pharmacies. 
Medical costs were relevant to direct medical costs, including 
the costs for outpatient clinics or hospital stays, laboratory tests, 
and drugs which were consumed due to epilepsy or seizure. We 
compared the costs with those of other developed countries. 
We selected comparable national studies which estimated the 
costs of general epilepsy, neither restricted to refractory epilep-
sy nor to specific institutions. We assessed the direct cost, in the 
form of total cost on epilepsy, the proportion of national expen-
diture on health, cost per patient, and the proportion of GDP per 
capita. For comparison, estimates from different countries were 
converted into US dollars using purchasing power parities (PPP) 
of survey year. National expenditure on health, GDP per capita 
and PPP were obtained from OECD health data, published in 
2009 (14). 
Ethics statement
This study was approved by the institutional review board of 
Kangwon National University Hospital (approval number: 1105-
AFCR-025). Informed consent was waived by the board.
RESULTS
Prevalence
During 2007, 119,722 patients (2.41/1,000) were found to have 
received anticonvulsants under the diagnostic codes of seizure 
or epilepsy. Gender-specific prevalence was higher in men (2.66/ 
1,000) than in women (2.16/1,000) in all age groups. Its preva-
lence was the lowest in those in their 30s and 40s, and increased 
from the 50s age group in men, whereas the prevalence was near-
ly constant from the 40s age group in women (Table 1).
  The prevalence of epilepsy was higher among those with a 
lower economic status in all age groups. The patients receiving 
medical aid were 16,713 (14.0%) in the patients registered with 
epilepsy, in contrast to 3.73% in the overall population. The prev-
alence was 9.02/1,000 for those receiving medical aid, and 2.15/ 
1,000 for those with health insurance. Even among those aged Lee S-Y, et al.  •  Prevalence of Epilepsy in Korea
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less than 20 yr, for whom health care is determined by their par-
ents’ economic and employment statuses, the prevalence of 
epilepsy was higher for those receiving medical aid (6.84/1,000 
vs 2.80/1,000) (Table 1).
  Age-standardized regional prevalence for diagnostic codes 
representing epilepsy or seizure was the highest in Jeju (7.41/ 
1,000) and the lowest in Ulsan (4.02/1,000). Jeonnam, Jeonbuk, 
Gangwon, Chungnam, Gwangju, and Chungbuk followed Jeju 
in order of prevalence (Fig. 1). The prevalence was higher in prov-
inces (5.04/1,000) than in metropolitan cities (4.55/1,000).
Anticonvulsant prescribing patterns
The mean number of AEDs prescribed per patient during 2007 
was 1.76. New anticonvulsants were more frequently used in pa-
tients aged less than 20 yr (Table 2). In order of decreasing fre-
quency, valproate, carbamazepine, and topiramate were the 
most commonly prescribed medications in all patients. In wom-
en, valproate was less frequently prescribed and topiramate 
and lamotrigine were more frequently prescribed (Fig. 2A). Val-
proate was prescribed most frequently those younger than 30 yr 
Table 1. Prevalence per 1,000 population according to age, gender, and economic 
status 
Age (yr) Total
Gender Health security system
Men Women
Health  
insurance
Medical  
aid
0-9 2.57 2.71 2.43 2.68   7.71
10-19 2.77 2.98 2.53 2.89   6.37
20-29 2.48 2.70 2.24 2.53 20.44
30-39 2.25 2.42 2.07 2.20 22.88
40-49 2.23 2.46 1.99 2.02 16.72
50-59 2.25 2.52 1.97 2.16 12.47
60-69 2.41 2.89 1.98 2.49   6.01
70 ≤ 2.45 3.17 2.02 2.37   3.19
All 2.41 2.66 2.16 2.15   9.02
Fig. 1. Regional prevalence in Korea. Note that the prevalence for each region was 
based on the diagnostic codes, irrespective of anticonvulsant prescription, because 
merging data for the residential areas and for the anticonvulsants was not permitted 
by privacy policy. Darker shades indicate higher prevalence. Numbers are the age-
standardized prevalences per 1,000 of the population in each region. 
Table 2. Number of anticonvulsants prescribed per a patient
Age (yr)
Old  
anticonvulsants
New  
anticonvulsants
 Total
0-9 0.78 0.93   1.71
10-19 0.70 1.16   1.86
20-29 0.98 0.98   1.96
30-39 1.08 0.82 1.9
40-49 1.09 0.69   1.78
50-59 1.01 0.61   1.62
60-69 0.89 0.54   1.43
70 ≤ 0.81 0.51   1.32
All 0.93 0.83   1.76
Female
Male
	 VPA	 CBZ	 TPM	LMT	 OCZ	 DPH	 Pb	 GBP	 ZNS	 LVT	 VGB	 PGB	 ETX
0.6
0.5
0.4
0.3
0.2
0.1
0
A B
70	≤ VPA CBZ GBP PHT Others
60-69 VPA PHT GBP Others
50-59 CBZ VPA TPM PHT Others
40-49 CBZ VPA TPM LMT Others
30-39 CBZ VPA TPM LMT Others
20-29 VPA CBZ TPM LMT Others
10-19 VPA TPM LMT OCZ Others
0-9 VPA OCZ TPM LMT Others
CBZ
Fig. 2. Anticonvulsant prescribing pattern according to gender (A) and age (B). (A) The vertical axis indicates the frequency of prescription (the number of patients who were 
prescribed the anticonvulsant divided by the number of entire patients who were prescribed any anticonvulsants under the diagnosis of epilepsy or seizure). (B) The length of 
horizontal axis was proportionated with the number of patients who took the anticonvulsant. The anticonvulsants were arranged in order of decreasing use from left to right. VPA, 
valproate; CBZ, carbamazepine; TPM, topiramate; LMT, lamotrigine; OCZ, oxcarbazepine; DPH, phenytoin; Pb, phenobarbital; GBP, gabapentin; ZNS, zonisamide; LVT= leveti-
racetam; VGB, vigabatrin; PGB, pregabalin; ETX, ethosuximide.Lee S-Y, et al.  •  Prevalence of Epilepsy in Korea
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and older than 70 yr, whereas carbamazepine was prescribed 
most frequently prescribed in the other age groups (Fig. 2B). 
Medical costs
Total annual medical cost in 2007 was US$183,376,382 (adjust-
ed to 2007 purchasing power parities), which equated to 0.46% 
of the total medical expenditure covered by the health security 
system (12) and 0.27% of total health expenditure (12, 14). The 
average annual cost per individual was US$759. Costs were high-
er for patients receiving medical aid than for those with health 
insurance, particularly hospitalization costs (Table 3). The cost 
on epilepsy or seizure as a percentage of national expenditure 
on health or GDP was lower than those of the UK (15) and the 
US (16), and the results are summarized in Table 4.
DISCUSSION
The prevalence of epilepsy found in the Korean population in 
the present study is comparable to those of population-based 
contemporary studies performed in developed countries. Re-
cord-based studies (2.7-17.6/1,000) generally estimate a preva-
lence lower than a door-to-door survey (2.2-41.0/1,000) (1). Our 
criteria for defining the epilepsy patient as a person who was 
prescribed anticonvulsant under a diagnosis suggestive of sei-
zure or epilepsy are the most reasonable criteria for selecting 
epilepsy patients from the administrative database. We included 
R56 (convulsion) because many clinicians use this code even 
for longstanding epilepsy because of stigma. Fisher et al. (17) 
on behalf of International League Against Epilepsy (ILAE) and 
International Bureau for Epilepsy (IBE) proposed the definition 
of epilepsy as at least single seizure with predisposition to gen-
erate epileptic seizures. Even if the patient with diagnostic code 
of R56 had a single seizure, the prescription of anticonvulsant 
can be interpreted that clinicians judged that the patient was 
predisposed to have further epileptic seizure, although acute 
symptomatic seizures which needed short term anticonvulsants 
cannot be excluded. 
  However, this statistics can miss the patients who are not re-
imbursed from NHI. The patients with posttraumatic epilepsy 
which are reimbursed from automobile insurance, industrial 
accident compensation insurance or the Ministry of Patriots 
and Veterans Affairs, those who take anticonvulsants from vol-
unteer organization such as Rose club, and those who chose to 
use alternative medicine are the cases. In addition, the preva-
lence measured in this study is for the treated epilepsy. For the 
prevalence of entire epilepsy, the treatment gap should be ob-
tained. Overall, the prevalence in this study could be underesti-
mated, but the margin of difference is likely to be small, because 
medical facilities are readily accessible and 70%-100% of anti-
convulsant costs are covered by the health security system.
  Men predominated in all age groups in the present study. The 
effect of concealment by women may be minimal, because this 
study was not based on self-reports but on medical records. This 
higher prevalence in men has also been found in the majority 
of European and North American studies (1), and has been re-
ported in India (18) and Vietnam (19). On the other hand, a fe-
male predominance has been reported by many African and 
South American studies (1, 20).
  In the present study, the prevalence of epilepsy was lowest   
in those in their thirties and forties. The pattern of age-specific 
prevalence may be because childhood epilepsies are prevalent 
at younger ages and various brain injuries accompanying epi-
lepsy increase in older age. Furthermore, prevalence increased 
in men from age 50 yr, whereas it remained nearly constant in 
women. The similar pattern was shown in a Finland study (21). 
A greater male dominance after the age of 50 may be due to a 
greater exposure to brain injury. The prevalence of epilepsy due 
Table 3. Annual medical costs for epilepsy or seizure
Annual costs (US$)*  Hospitalization   Outpatient clinic                     Pharmacy     Total 
Health insurance 
   Total 
   Per patient 
 
36,772,275
191
 
31,439,476
162
 
56,639,566
293
 
 124,851,318
               646
Medical aid 
   Total 
   Per patient 
 
35,996,593
740
 
17,694,165
364
 
4,834,306
99
 
   58,525,064
             1203
Total
   Total 
   Per patient 
 
72,768,868
301
 
49,133,641
203
 
61,473,872
254
 
183,376,382
† 
               759
*Adjusted to 2007 US dollars; 
†0.46% of total medical expenditure.
Table 4. Comparison of medical costs for epilepsy
Items
   Korea  
   (present  
   study)
  UK (15) USA (16)
Year of estimate 2007 1990 2004
Direct cost on epilepsy 
   (thousand US$, PPP of the survey year)
183,376 262,728 9,488,530
Direct cost on epilepsy/
   national expenditure on health (%) 
0.27 0.47 0.52
Direct cost per patient 
   (US$, PPP of the survey year)
749 614 4,523
Direct cost per patient/
   GDP per capita (%)
3.46 3.76 11.6
PPP, purchasing power parities.Lee S-Y, et al.  •  Prevalence of Epilepsy in Korea
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to organic cause was higher in men than women, whereas the 
prevalence of epilepsy due to unknown cause seems to be of the 
same in both genders (21, 22).
  Epilepsy was more prevalent in those with a low economic 
status. For working-age people, a low economic status may be 
the result of epilepsy, which can deprive individuals of employ-
ment opportunities. However, the higher prevalence in low eco-
nomic status, even in people younger than 20 who were eco-
nomically inactive, suggests that low economic status increases 
the risk of epilepsy. This is consistent with the results of an inci-
dence study performed in UK (23). However, an Icelandic study 
showed that socioeconomic status was a risk factor for adults 
but not for children (24). A low economic status could affect the 
development of epilepsy due to perinatal problems, poor nutri-
tion and hygiene, infection, trauma, or genetic factors.
  Regional differences in prevalence can be attributed to geo-
graphic and economic factors. The region with the highest prev-
alence was Jeju. Jeju is the largest island located 59 km from the 
mainland and is unique in terms of its gene pool, environment 
and culture. In addition, it is a representative endemic area of 
cysticercosis (25), which has been attributed to the local method 
of breeding pigs. In the southwestern region of the mainland, 
prevalence reduced with distance from Jeju. Gangwon, one of 
the regions with high prevalence, is also isolated and a relatively 
underdeveloped area because it is mountainous. The area with 
the lowest prevalence, Ulsan, is the richest area in Korea (26). 
Among the areas with low prevalence, the northwestern area is 
the capital region, and the southeastern area also developed 
earlier and is separated from the southwestern area by the So-
baek Mountains. The higher prevalence of epilepsy in provinces 
than in metropolitan cities can be similarly interpreted. It is un-
certain whether economic factors have been a cause or a con-
founding factor, because disabled persons tend to stay in rural 
areas, whereas healthy persons tend to move to urban areas. 
Prevalence for each region could be overestimated because it 
was based on the diagnostic codes, irrespective of anticonvul-
sant prescription. 
  The prescribing pattern was generally reasonable considering 
the profiles of anticonvulsant characteristics. Valproate is not 
readily recommended for women of reproductive age because 
of teratogenic and hormonal adverse effects, whereas lamotrig-
ine has been reported to have little effect on reproduction, at 
dose of less than 200 mg (27, 28). Topiramate could be more 
preferred by women because of its weight-reducing effect (29). 
The more frequent use of valproate among younger age groups 
is probably explained by their higher proportion of generalized 
epilepsy. The use of new anticonvulsants was much higher than 
that of old anticonvulsants in younger age groups. The use of 
new anticonvulsants was also quite prevalent among older age 
groups, considering that many patients had been taking anti-
convulsants before the introduction of new anticonvulsants.
  The cost that we calculated is relevant to direct medical costs. 
It did not include the costs for nonmedical items and unemploy-
ment, which range between 12% and 85% of total annual costs 
(30). Therefore, the economic burden of epilepsy would be high-
er than the above results.
  The higher cost for patients who receive medical aid suggests 
that there may be a higher prevalence of more severe cases or 
possible overuse of medical services by individuals in this group. 
The direct costs on epilepsy were lower than those of the UK (15) 
and the US (16), although there are some differences in the in-
clusion criteria for the costings.
  There is a potential bias and limitation in present study. The 
diagnostic codes can be missed, uncertain or manipulated for 
reimbursement. However, we believe that the level of false reg-
istration was negligible because of stigma following registration 
and no reimbursement in case of missing registration. The ac-
curacy of the case ascertainment method with anticonvulsant 
prescription and diagnostic codes from NHI data should be val-
idated in further studies. In spite of several limitations, this study 
is meaningful because it is the first epidemiologic study to be 
conducted on epilepsy in Korea, and one of few nationwide 
studies on an unselected population.
  In conclusion, epilepsy prevalence in Korea is comparable to 
that in developed countries. Economic status and geography 
affect the prevalence of epilepsy. 
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